Clinical trials: Drug Eluting Stents
Coronary Artery Disease
Smart Angioplasty Research Team-Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion With Drug-Coated Balloon
A prospective, multi-center, open-label, randomized controlled, superiority trial. The aim of the study is to compare clinical outcomes between upfront 2-stenting strategy versus upfront drug-coated balloon (DCB)-based hybrid…
- Trial name
- SMART-DCB (NCT07019350)
- Testing
- Upfront DCB-based hybrid strategy, Upfront 2-stenting strategy
- Where
- 3 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
The purpose of the EVOLVE Trial is to assess the safety and performance of the everolimus-eluting Evolution stent for the treatment of a de novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 mm…
- Trial name
- Evolve (NCT01135225)
- Testing
- PROMUS(TM) Element (TM) Stent System, Evolution Stent System
- Where
- 29 sites in Australia, Belgium and 7 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Symptomatic Intracranial Atherosclerotic Stenosis
Drug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis
This investigation is a prospective, multicenter, randomized controlled, non-inferiority clinical trial, to evaluate the safety and efficacy of the investigational device against alternative models/specifications of the control…
- Trial name
- DESIAS (NCT07197970)
- Testing
- NxiDIME™ Intracranial Drug-Eluting Stent System, NOVA DES Intracranial Drug-Eluting Stent
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Beijing Tiantan Hospital
Coronary Artery Disease
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient…
- Trial name
- PIONEER-IV (NCT04923191)
- Testing
- Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
- Where
- 19 sites in Belgium, Ireland and 3 more
- Volunteers
- 2,540 people
- Sponsor
- National University of Ireland, Galway, Ireland
Coronary Artery Disease
Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions
The primary objective of Infinnium-Core™ Registry is to assess the safety and efficacy of the Infinnium-Core™ Paclitaxel Eluting Coronary Stent System in de novo Coronary Lesions.
- Trial name
- NCT00936780
- Testing
- Infinnium-Core™ Paclitaxel eluting Coronary Stent
- Where
- 7 sites in India
- Volunteers
- 67 people
- Sponsor
- Sahajanand Medical Technologies Limited
De Novo Stenosis, Coronary Artery Disease
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
Coronary restenosis has been one of the main reasons affecting the prognosis of patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI).
- Conditions
- De Novo Stenosis, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- CAGE-FREEIII (NCT05209412)
- Testing
- Lepu Paclitaxel coated balloon, Resolute Integrity Zotarolimus eluting stents, Aspirin
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndrome, Stable Chronic Angina
Angiographic Control Vs. Ischemia-driven Management of Patients Treated with PCI on Left Main with Drug-eluting Stents
The present study aims to compare a planned angiographic control (PAC) follow-up strategy vs. conservative management for patients treated with drug-eluting stents on unprotected left main artery in a prospective, randomized…
- Conditions
- Acute Coronary Syndrome, Stable Chronic Angina, Coronary Artery Disease, Left Main Coronary Artery Disease
- Trial name
- PULSE (NCT04144881)
- Testing
- coronary computed tomography
- Where
- 3 sites in Italy
- Volunteers
- 606 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Heart Diseases, Cardiovascular Diseases
Trial Evaluating New Strategy in the Functional Assessment of 3-vessel Disease Using SYNTAXII Score in Patients With PCI
Clinical study that aims to evaluate a new strategy using the SYNTAX II Score calculator in the functional assessment of patients with new coronary 3-vessel-disease who undergo percutaneous coronary intervention (PCI)
- Conditions
- Heart Diseases, Cardiovascular Diseases, 3 Vessel Coronary Artery Disease
- Trial name
- NCT02015832
- Testing
- Coronary stent, Multi Slice Computed Tomography, instantaneous wave-free ratio
- Where
- 22 sites in Netherlands, Poland and 2 more
- Volunteers
- 454 people
- Sponsor
- ECRI bv
Coronary Artery Disease
Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent
SORT OUT XI Comparison of Combo™ stent and BioMatrix Alpha™ stent in the treatment of unselected patients with ischemic heart disease.
- Trial name
- SORTOUTXI (NCT03952273)
- Testing
- PCI with BioMatrix Alpha™ stent, PCI with Combo™ stent
- Where
- 2 sites in Denmark
- Volunteers
- 3,141 people
- Sponsor
- Phillip Freeman
Coronary Artery Disease, Coronary Restenosis
DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold
The aim of the study is to compare angiographic outcomes following revascularization using drug-eluting balloon (DEB) versus 2nd generation drug-eluting stent (DES) in treatment of Bioresorbable Vascular Scaffold Restenosis.
- Trial name
- SMART-BRS-ISR (NCT03074305)
- Testing
- PCI for in-bioresorbable scaffold stenosis
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Coronary Arteriosclerosis
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
To evaluate the safety, efficacy and deliverability of the Combo bio-engineered sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the treatment of patients with de novo stenotic lesions of native…
- Trial name
- RECOVERY (NCT02542007)
- Testing
- OrbusNeich Combo stent™, sirolimus-eluting stent system
- Where
- 15 sites in China
- Volunteers
- 440 people
- Sponsor
- OrbusNeich
Coronary Artery Disease
e-BioMatrix PostMarket Registry
The purpose of this registry is to capture clinical data of the BioMatrix™ and BioMatrix Flex™ (Biolimus A9™-Eluting) stent systems in relation to safety and effectiveness.
- Trial name
- eBMX-PMR (NCT01289002)
- Where
- 69 sites in Austria, Czechia and 14 more
- Volunteers
- 5,652 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
Supralimus-Core™ Pharmacokinetic (PK) Study
The primary objective of this study is to evaluate the pharmacokinetic (PK) and safety associated with Supralimus-Core™ Sirolimus Eluting Coronary Stent system in the treatment of single de novo lesions in native coronary…
- Trial name
- NCT01121744
- Testing
- Supralimus-Core™ Sirolimus eluting Coronary Stent
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Sahajanand Medical Technologies Limited
Chronic Coronary Syndrome
Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons
The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions.
- Trial name
- TITAN-DEB (NCT05674630)
- Testing
- Magic Touch drug eluting balloon based strategy, Drug-eluting stent-based strategy
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- Cardiocentro Ticino
Coronary Artery Disease
DESTINY TRIAL (Inspiron x Biomatrix)
The main objective of this study is to evaluate the effectiveness of stent Inspiron ™ sirolimus-eluting and coating the abluminal biodegradable stent Biomatrix Flex ™ lesions in native coronary arteries.
- Trial name
- NCT01856088
- Testing
- Inspiron Stent, Biomatrix Flex Stent
- Where
- 10 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Scitech Produtos Medicos SA
ST Elevation Myocardial Infarction
3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
To compare the clinical outcomes of dual antiplatelet therapy with aspirin and P2Y12 receptor inhibitor vs. ticagrelor monotherapy at 3 months after PCI in patients with ST-elevation myocardial infarction.
- Trial name
- BULK-STEMI (NCT04570345)
- Testing
- ticagrelor monotherapy, Aspirin with P2Y12 receptor inhibitor
- Where
- South Korea
- Volunteers
- 1,002 people
- Sponsor
- Dong-A University
Coronary Artery Disease
Intra-patient Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT (Optical Coherence Tomography) Follow up
The objective of the study is to evaluate the process of early re-endothelialization of the Coroflex® ISAR Drug-eluting stent compared with the Ultimaster® Drug-eluting stent
- Trial name
- NCT02785237
- Testing
- Coroflex® ISAR Drug-eluting stent, Ultimaster® Drug-eluting stent
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Coronary Artery Disease, Coronary Restenosis
SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents
This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug eluting stents.
- Trial name
- NCT00714545
- Testing
- Intracoronary brachytherapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Scripps Health
Coronary Artery Disease
ABSORB II Randomized Controlled Trial
Prospective, randomized (2:1), active control, single blinded, parallel two-arm, multi-center clinical investigation using Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System (ABSORB BVS); compared to…
- Trial name
- ABSORB II (NCT01425281)
- Testing
- Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System, Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
- Where
- Belgium
- Volunteers
- 501 people
- Sponsor
- Abbott Medical Devices
Stents, Neointimal Proliferation
Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents
Background: Safety concerns regarding use of drug eluting stent systems (DES) are related mostly to late stent thrombosis, which is facilitated by incomplete stent endothelial coverage.
- Trial name
- OCTOPUS (NCT01056744)
- Testing
- Percutaneous coronary intervention with stent implantation
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- University of Jena